We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stick With These Health Care Leaders in the Second Half of 2022
Read MoreHide Full Article
It’s certainly been a year for the history books, as concerns over heightened inflation, slower earnings growth, and a potential recession have weighed heavily on risk assets. While this market has been difficult to navigate for even the most seasoned investor, there are steps we can take to mitigate the volatility and benefit our portfolio as we move further into the second half of the year.
Having a plan in place that takes into account multiple outcomes can give us the confidence to tackle this dynamic market. If there’s one thing we know for sure, it’s that stocks won’t shoot up in a straight line over the next few months. It appears stocks found support at an important technical level back in June, but it remains to be seen if that will mark the low for the year. We are in the midst of the third quarter of a mid-term year, which historically has been quite weak.
Knowing that volatility will likely rear its ugly head once again over the next few months, we want to target stocks that have weathered this year’s bear market extremely well. Only stocks that are in the most powerful uptrends are trading near new highs during uncertain times like the present. So how do we go about selecting stocks for our portfolio? We let the market guide us in our selection process, and we employ the various Zacks Ranking Systems to help us identify stocks with the best profit potential.
Using a top-down approach, the Zacks Medical Sector is currently ranked in the top 25% out of all Zacks Ranked Sectors. This sector contains companies that serve the health care space and provide medical and dental products, pharmaceuticals, insurance services, biomedical and genetic engineering, and drug prescription services.
Drilling further down, the Zacks Medical – HMOs industry is the leading industry group within this sector. The Medical – HMOs industry is ranked in the top 17% out of approximately 250 industry groups. Digging a bit deeper, this group has widely outperformed the major indices this year with a +8.11% return. Quantitative research studies have shown that approximately half of a stock’s future price appreciation is due to its industry grouping. Also note the favorable characteristics for this industry:
Image Source: Zacks Investment Research
By investing in stocks within leading industry groups, we can provide a constant ‘tailwind’ to our investing success. Let’s take a look at two companies within this top sector and industry combination.
Humana is a health benefits and well-being company in the United States. HUM provides medical and supplemental benefits to individuals through Health Maintenance Organization (HMO), Private Fee-For-Service (PFFS), and Preferred Provider Organization (PPO) plans. The company also has contracts with various states to provide Medicaid and long-term support services.
Humana has built a considerable membership base, with over 17 million members under its medical plans and over 7 million members in its specialty product category. In total for 2022, revenues are projected to increase 11.79% to $92.86 billion. Earnings are expected to climb 20.01% to $24.77 per share. The long-term trends illustrated below are what the bulls like to see.
Image Source: Zacks Investment Research
HUM has strung together an impressive track record in terms of earnings beats, having exceeded estimates in each quarter for the past five years running. The health provider most recently announced Q2 EPS last week of $8.67/share, a 13.04% surprise over the $7.67/share consensus estimate. HUM has delivered a trailing four-quarter average earnings surprise of 9.09%.
Image Source: Zacks Investment Research
The stock is up better than 3% this year while the market hovers in bear market territory, and is currently hovering near new all-time highs – a big sign of strength.
Centene operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. The company offers health coverage through government subsidized programs including Medicaid, the State children’s health insurance program, and long-term support services.
On the heels of an uptick in Medicaid memberships, CNC sales are expected to leap 14.1% in 2022 to $143.75 billion. Earnings should also grow at a healthy clip, with estimates calling for 10.49% growth ($5.69/share) relative to last year. CNC also reported Q2 earnings last week, posting EPS of $1.77/share, a 2.31% beat over consensus estimates.
Image Source: Zacks Investment Research
CNC is undervalued (16.35 forward P/E) relative to its industry group (18.84 forward P/E). The stock is up nearly 13% this year and is also breaking out to an all-time high.
Image Source: Zacks Investment Research
These two market leaders are well-established companies and have weathered the year’s volatility extremely well. Each of them boasts strong fundamentals, including the backing of a leading industry group. Make sure to keep an eye on HUM and CNC as we head into the second half of the year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Stick With These Health Care Leaders in the Second Half of 2022
It’s certainly been a year for the history books, as concerns over heightened inflation, slower earnings growth, and a potential recession have weighed heavily on risk assets. While this market has been difficult to navigate for even the most seasoned investor, there are steps we can take to mitigate the volatility and benefit our portfolio as we move further into the second half of the year.
Having a plan in place that takes into account multiple outcomes can give us the confidence to tackle this dynamic market. If there’s one thing we know for sure, it’s that stocks won’t shoot up in a straight line over the next few months. It appears stocks found support at an important technical level back in June, but it remains to be seen if that will mark the low for the year. We are in the midst of the third quarter of a mid-term year, which historically has been quite weak.
Knowing that volatility will likely rear its ugly head once again over the next few months, we want to target stocks that have weathered this year’s bear market extremely well. Only stocks that are in the most powerful uptrends are trading near new highs during uncertain times like the present. So how do we go about selecting stocks for our portfolio? We let the market guide us in our selection process, and we employ the various Zacks Ranking Systems to help us identify stocks with the best profit potential.
Using a top-down approach, the Zacks Medical Sector is currently ranked in the top 25% out of all Zacks Ranked Sectors. This sector contains companies that serve the health care space and provide medical and dental products, pharmaceuticals, insurance services, biomedical and genetic engineering, and drug prescription services.
Drilling further down, the Zacks Medical – HMOs industry is the leading industry group within this sector. The Medical – HMOs industry is ranked in the top 17% out of approximately 250 industry groups. Digging a bit deeper, this group has widely outperformed the major indices this year with a +8.11% return. Quantitative research studies have shown that approximately half of a stock’s future price appreciation is due to its industry grouping. Also note the favorable characteristics for this industry:
Image Source: Zacks Investment Research
By investing in stocks within leading industry groups, we can provide a constant ‘tailwind’ to our investing success. Let’s take a look at two companies within this top sector and industry combination.
Humana Inc. (HUM - Free Report)
Humana is a health benefits and well-being company in the United States. HUM provides medical and supplemental benefits to individuals through Health Maintenance Organization (HMO), Private Fee-For-Service (PFFS), and Preferred Provider Organization (PPO) plans. The company also has contracts with various states to provide Medicaid and long-term support services.
Humana has built a considerable membership base, with over 17 million members under its medical plans and over 7 million members in its specialty product category. In total for 2022, revenues are projected to increase 11.79% to $92.86 billion. Earnings are expected to climb 20.01% to $24.77 per share. The long-term trends illustrated below are what the bulls like to see.
Image Source: Zacks Investment Research
HUM has strung together an impressive track record in terms of earnings beats, having exceeded estimates in each quarter for the past five years running. The health provider most recently announced Q2 EPS last week of $8.67/share, a 13.04% surprise over the $7.67/share consensus estimate. HUM has delivered a trailing four-quarter average earnings surprise of 9.09%.
Image Source: Zacks Investment Research
The stock is up better than 3% this year while the market hovers in bear market territory, and is currently hovering near new all-time highs – a big sign of strength.
Centene Corp. (CNC - Free Report)
Centene operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. The company offers health coverage through government subsidized programs including Medicaid, the State children’s health insurance program, and long-term support services.
On the heels of an uptick in Medicaid memberships, CNC sales are expected to leap 14.1% in 2022 to $143.75 billion. Earnings should also grow at a healthy clip, with estimates calling for 10.49% growth ($5.69/share) relative to last year. CNC also reported Q2 earnings last week, posting EPS of $1.77/share, a 2.31% beat over consensus estimates.
Image Source: Zacks Investment Research
CNC is undervalued (16.35 forward P/E) relative to its industry group (18.84 forward P/E). The stock is up nearly 13% this year and is also breaking out to an all-time high.
Image Source: Zacks Investment Research
These two market leaders are well-established companies and have weathered the year’s volatility extremely well. Each of them boasts strong fundamentals, including the backing of a leading industry group. Make sure to keep an eye on HUM and CNC as we head into the second half of the year.